IM Cannabis (NASDAQ:IMCC) has entered into a definitive agreement to sell IMC Holdings and its European-focused assets to Slil.com Holding, a transaction management expects to improve shareholders’ equity by approximately C$3 million while reducing liabilities and simplifying the company’s structure.
The proposed European asset sale would leave IM Cannabis focused on its Israeli medical cannabis operations, but investors must also weigh the company’s stated financial difficulties and the related-party nature of the deal.
Key Investor Takeaways
- IM Cannabis (NASDAQ:IMCC) expects the transaction to improve shareholders’ equity by approximately C$3 million based on management’s current pro forma analysis.
- Slil will assume retained liabilities of up to approximately C$9.4 million, unless the parties mutually agree to an adjustment.
- The consideration also includes C$3 million of advance payments previously made to IM Cannabis by Slil and an affiliate.
- IMCC will retain its core Israeli medical cannabis operations, while European-focused assets including Germany’s Adjupharm GmbH will move with IMC Holdings.
- The transaction is a related-party deal because Slil is controlled by IM Cannabis CEO, director, securityholder and debtholder Oren Shuster.
Why IMCC Stock Is in Focus
IM Cannabis signed the definitive share purchase agreement on August 16, following its earlier June 18 announcement concerning the transaction.
Before closing, the company will reorganize IMC Holdings so that its Israeli operations are transferred out and remain with IMCC. IMC Holdings will then principally hold equity interests in Adjupharm GmbH, Xinteza API Ltd. and Shiran Societe Anonyme, alongside specified retained liabilities.
Slil has agreed to acquire all outstanding shares of IMC Holdings. Consideration consists of C$3 million in advance payments already made to IM Cannabis, together with the assumption of retained liabilities that will not materially exceed C$9.4 million unless otherwise agreed.
No IMCC or IMC Holdings securities will be issued or exchanged under the agreement. The transaction has an outside closing date of September 30, 2026.
Why This Matters for Investors
The central financial issue is balance-sheet improvement. IM Cannabis expects the disposal to increase shareholders’ equity by approximately C$3 million, reduce liabilities connected with IMC Holdings and improve working capital.
That could leave IMCC with a simpler operating structure centred on its Israeli medical cannabis business. The company said it intends to focus resources on those retained operations while continuing to evaluate additional opportunities.
However, the transaction also carries governance considerations. Slil is beneficially owned and controlled by Oren Shuster, IM Cannabis’ chief executive officer, director, securityholder and debtholder, making the disposal a related-party transaction under MI 61-101.
IM Cannabis intends to rely on financial hardship exemptions from formal valuation and minority shareholder approval requirements. Among the reasons cited, the company said it is in serious financial difficulty and that the transaction is intended to improve its financial position.
Those disclosures make the balance-sheet impact and transaction process particularly relevant for investors assessing the strategic reset.
The board has established a special committee consisting solely of independent directors to evaluate the transaction. It has also commissioned Beta Finance T.Y.S Ltd. to provide a valuation or financial analysis to assist the committee and board, although that work will not constitute a formal valuation under MI 61-101.
What to Watch Next
Closing remains dependent on several conditions, including completion of the pre-closing reorganisation, receipt of a valid tax certificate from the Israel Tax Authority and other required approvals and consents.
Investors can also watch for the forthcoming material change report, which is expected to provide additional information on the related-party transaction and Beta Finance analysis.
IM Cannabis expects the transaction to close less than 21 days after filing that report, citing its financial condition, liquidity position, debt obligations and the anticipated benefits of an expedited completion. September 30, 2026 is the outside date for closing.